Editas Medicine, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for the
Condensed Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 97,866,996 | $10 | $1,655,781 | $— | $(1,628,503) | $27,288 |
| Vesting of restricted common stock awards | 34,038 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,102 | — | — | 2,102 |
| Net loss | — | — | — | — | (24,982) | (24,982) |
| Balance at March 31, 2026 | 97,901,034 | $10 | $1,657,883 | $— | $(1,653,485) | $4,408 |
| Issuance of common stock and warrants to purchase future common stock from financing | 55,555,556 | 5 | 116,875 | — | — | 116,880 |
| Exercise of stock options | 20,040 | — | 36 | — | — | 36 |
| Stock-based compensation expense | — | — | 2,193 | — | — | 2,193 |
| Vesting of restricted common stock awards | 54,268 | — | — | — | — | — |
| Unrealized loss on marketable debt securities | — | — | — | (6) | — | (6) |
| Net loss | — | — | — | — | (18,230) | (18,230) |
| Balance at June 30, 2026 | 153,530,898 | $15 | $1,776,987 | $(6) | $(1,671,715) | $105,281 |
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 82,734,696 | $8 | $1,602,441 | $268 | $(1,468,443) | $134,274 |
| Issuance of common stock from at-the-market equity offering, net | 706,236 | — | 1,435 | — | — | 1,435 |
| Vesting of restricted common stock awards | 268,604 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,979 | — | — | 2,979 |
| Unrealized loss on marketable debt securities | — | — | — | (180) | — | (180) |
| Net loss | — | — | — | — | (76,088) | (76,088) |
| Balance at March 31, 2025 | 83,709,536 | $8 | $1,606,855 | $88 | $(1,544,531) | $62,420 |
| Issuance of common stock from at-the-market equity offering, net | 3,419,836 | 1 | 7,184 | — | — | 7,185 |
| Stock-based compensation expense | — | — | 2,664 | — | — | 2,664 |
| Vesting of restricted common stock awards | 102,894 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 156,159 | — | 228 | — | — | 228 |
| Unrealized loss on marketable debt securities | — | — | — | (73) | — | (73) |
| Net loss | — | — | — | — | (53,235) | (53,235) |
| Balance at June 30, 2025 | 87,388,425 | $9 | $1,616,931 | $15 | $(1,597,766) | $19,189 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.